Literature DB >> 19099201

Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors.

Masayuki Kanamori1, Toshihiro Kumabe, Yukihiko Sonoda, Yoshikazu Nishino, Mika Watanabe, Teiji Tominaga.   

Abstract

The pattern of recurrence and predictive factors for tumor progression, dissemination and survival in oligodendroglial tumors were investigated. 56 consecutive patients with oligodendroglial tumors were retrospectively analyzed to determine the predictive significance of various factors, including World Health Organization grade, loss of chromosomes 1p and 19q, and immunohistochemical features of TP53, O(6)-methylguanine-deoxyribonucleic-acid-methyltransferase, CD44H, nestin, and Ki-67. Eleven patients developed dissemination, and had significantly shorter post-progression survival compared to ten patients with local recurrence. Univariate analysis showed that retention of chromosome 1p or 19q, Ki-67 labeling index > or = 25%, diffuse expression of nestin, and p53 labeling index > or = 10% were unfavorable factors for overall, progression-free, and dissemination-free survival. Multivariate analysis showed that Ki-67 labeling index > or = 25% and diffuse expression of nestin were significant for dissemination-free survival. In conclusion, post-progression survival shows significant differences between patients with local and disseminated recurrence. Ki-67 labeling index and nestin expression pattern are useful markers to predict dissemination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19099201     DOI: 10.1007/s11060-008-9762-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  Survival analysis of presumptive prognostic markers among oligodendrogliomas.

Authors:  Roger E McLendon; James E Herndon; Bryan West; David Reardon; Rodney Wiltshire; B K Ahmed Rasheed; Jennifer Quinn; Henry S Friedman; Allan H Friedman; Darell D Bigner
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

Review 2.  Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment.

Authors:  D Fortin; G J Cairncross; R R Hammond
Journal:  Neurosurgery       Date:  1999-12       Impact factor: 4.654

Review 3.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  J Neuropathol Exp Neurol       Date:  2005-06       Impact factor: 3.685

4.  Nestin small interfering RNA (siRNA) reduces cell growth in cultured astrocytoma cells.

Authors:  Li-Chun Wei; Mei Shi; Rong Cao; Liang-Wei Chen; Ying-Shing Chan
Journal:  Brain Res       Date:  2007-11-22       Impact factor: 3.252

5.  Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.

Authors:  Netta Levin; Iris Lavon; Bracha Zelikovitsh; Dana Fuchs; Felix Bokstein; Yakov Fellig; Tali Siegal
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

6.  DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

Authors:  H S Friedman; R E McLendon; T Kerby; M Dugan; S H Bigner; A J Henry; D M Ashley; J Krischer; S Lovell; K Rasheed; F Marchev; A J Seman; I Cokgor; J Rich; E Stewart; O M Colvin; J M Provenzale; D D Bigner; M M Haglund; A H Friedman; P L Modrich
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

7.  Dissemination of supratentorial malignant gliomas via the cerebrospinal fluid in children.

Authors:  P A Grabb; A L Albright; D Pang
Journal:  Neurosurgery       Date:  1992-01       Impact factor: 4.654

8.  Glioma invasion--pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumorsuppressor p53 and proto-oncogene ETS-1.

Authors:  A Giese
Journal:  Acta Neurochir Suppl       Date:  2003

9.  PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma.

Authors:  Hideaki Kato; Miki Fujimura; Toshihiro Kumabe; Chikashi Ishioka; Ryunosuke Kanamaru; Takashi Yoshimoto
Journal:  J Clin Neurosci       Date:  2004-01       Impact factor: 1.961

10.  Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications.

Authors:  Annunziato Mangiola; Gina Lama; Cecilia Giannitelli; Pasquale De Bonis; Carmelo Anile; Libero Lauriola; Giuseppe La Torre; Giovanni Sabatino; Giulio Maira; Meena Jhanwar-Uniyal; Gigliola Sica
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

View more
  12 in total

1.  Clinical value of CD133 and nestin in patients with glioma: a population-based study.

Authors:  Rikke H Dahlrot; Steinbjørn Hansen; Stine S Jensen; Henrik D Schrøder; Jacob Hjelmborg; Bjarne W Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 2.  What is the clinical value of cancer stem cell markers in gliomas?

Authors:  Rikke Hedegaard Dahlrot; Simon Kjær Hermansen; Steinbjørn Hansen; Bjarne Winther Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

3.  Interventricular low-grade oligodendroglioma with multiple parenchymal relapse.

Authors:  Ali Akhavan; Fariba Binesh; Afshin Rakhsha; Hossein Navabii
Journal:  BMJ Case Rep       Date:  2012-06-08

4.  Nestin Expression Is Associated with Poor Clinicopathological Features and Prognosis in Glioma Patients: an Association Study and Meta-analysis.

Authors:  Donglai Lv; Lin Lu; Zongtao Hu; Zhenle Fei; Meiqin Liu; Lei Wei; Jun Xu
Journal:  Mol Neurobiol       Date:  2016-01-14       Impact factor: 5.590

5.  Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.

Authors:  Yoshinari Osada; Ryuta Saito; Satoshi Miyata; Takuhiro Shoji; Ichiyo Shibahara; Masayuki Kanamori; Yukihiko Sonoda; Toshihiro Kumabe; Mika Watanabe; Teiji Tominaga
Journal:  Brain Tumor Pathol       Date:  2021-07-16       Impact factor: 3.298

6.  Incidence of initial spinal metastasis in glioblastoma patients and the importance of spinal screening using MRI.

Authors:  Ichiyo Shibahara; Ryuta Saito; Yoshinari Osada; Masayuki Kanamori; Yukihiko Sonoda; Toshihiro Kumabe; Shunji Mugikura; Mika Watanabe; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-11-09       Impact factor: 4.130

7.  IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.

Authors:  Ichiyo Shibahara; Yukihiko Sonoda; Masayuki Kanamori; Ryuta Saito; Yoji Yamashita; Toshihiro Kumabe; Mika Watanabe; Hiroyoshi Suzuki; Shunsuke Kato; Chikashi Ishioka; Teiji Tominaga
Journal:  Int J Clin Oncol       Date:  2011-10-06       Impact factor: 3.850

8.  Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm.

Authors:  Céline Duval; Marie de Tayrac; Karine Michaud; Florian Cabillic; Claudie Paquet; Peter Vincent Gould; Stéphan Saikali
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

9.  A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors.

Authors:  Rebecca Senetta; Ludovica Verdun di Cantogno; Luigi Chiusa; Isabella Castellano; Patrizia Gugliotta; Anna Sapino; Paola Cassoni
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

10.  Radiological assessment schedule for 1p/19q-codeleted gliomas during the surveillance period using parametric modeling.

Authors:  Ho Kang; Jongjin Lee; So Young Ji; Seung Won Choi; Kyung-Min Kim; Joo Ho Lee; Soon-Tae Lee; Jae Kyung Won; Tae Min Kim; Seung Hong Choi; Sung-Hye Park; Kyung-Sub Moon; Chae-Yong Kim; Heon Yoo; Do-Hyun Nam; Jeong Hoon Kim; Yongdai Kim; Chul-Kee Park
Journal:  Neurooncol Adv       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.